Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.52
NAS:LGND's Cash to Debt is ranked lower than
87% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. NAS:LGND: 0.52 )
Ranked among companies with meaningful Cash to Debt only.
NAS:LGND' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.5 Max: No Debt
Current: 0.52
Equity to Asset 0.64
NAS:LGND's Equity to Asset is ranked lower than
54% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:LGND: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
NAS:LGND' s Equity to Asset Range Over the Past 10 Years
Min: -0.83  Med: 0.12 Max: 0.68
Current: 0.64
-0.83
0.68
Interest Coverage 3.28
NAS:LGND's Interest Coverage is ranked lower than
93% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:LGND: 3.28 )
Ranked among companies with meaningful Interest Coverage only.
NAS:LGND' s Interest Coverage Range Over the Past 10 Years
Min: 0.06  Med: 4.04 Max: No Debt
Current: 3.28
F-Score: 6
Z-Score: 4.80
M-Score: 0.33
WACC vs ROIC
7.66%
87.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 44.38
NAS:LGND's Operating margin (%) is ranked higher than
96% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NAS:LGND: 44.38 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:LGND' s Operating margin (%) Range Over the Past 10 Years
Min: -1963.29  Med: -19.93 Max: 38
Current: 44.38
-1963.29
38
Net-margin (%) 265.53
NAS:LGND's Net-margin (%) is ranked higher than
99% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. NAS:LGND: 265.53 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:LGND' s Net-margin (%) Range Over the Past 10 Years
Min: -798.16  Med: 8.48 Max: 2184.64
Current: 265.53
-798.16
2184.64
ROE (%) 80.65
NAS:LGND's ROE (%) is ranked higher than
99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. NAS:LGND: 80.65 )
Ranked among companies with meaningful ROE (%) only.
NAS:LGND' s ROE (%) Range Over the Past 10 Years
Min: -1046.55  Med: 31.67 Max: 997.71
Current: 80.65
-1046.55
997.71
ROA (%) 45.13
NAS:LGND's ROA (%) is ranked higher than
98% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. NAS:LGND: 45.13 )
Ranked among companies with meaningful ROA (%) only.
NAS:LGND' s ROA (%) Range Over the Past 10 Years
Min: -56.92  Med: 3.08 Max: 112.83
Current: 45.13
-56.92
112.83
ROC (Joel Greenblatt) (%) 818.57
NAS:LGND's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. NAS:LGND: 818.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:LGND' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1252.88  Med: -214.44 Max: 6370.4
Current: 818.57
-1252.88
6370.4
Revenue Growth (3Y)(%) 28.90
NAS:LGND's Revenue Growth (3Y)(%) is ranked higher than
80% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. NAS:LGND: 28.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:LGND' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -65  Med: 6.2 Max: 91
Current: 28.9
-65
91
EBITDA Growth (3Y)(%) 112.50
NAS:LGND's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NAS:LGND: 112.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:LGND' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -76.7  Med: -13.9 Max: 112.5
Current: 112.5
-76.7
112.5
» NAS:LGND's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

LGND Guru Trades in Q3 2015

RS Investment Management 1,379,230 sh (+40.31%)
Ken Fisher 70,683 sh (-12.31%)
Jim Simons 72,200 sh (-24.87%)
» More
Q4 2015

LGND Guru Trades in Q4 2015

Paul Tudor Jones 2,468 sh (New)
Jim Simons 174,300 sh (+141.41%)
Ken Fisher 70,583 sh (-0.14%)
RS Investment Management 1,089,730 sh (-20.99%)
» More
Q1 2016

LGND Guru Trades in Q1 2016

Joel Greenblatt 21,822 sh (New)
Columbia Wanger 158,034 sh (New)
Paul Tudor Jones 3,900 sh (+58.02%)
Ken Fisher 70,583 sh (unchged)
RS Investment Management 912,545 sh (-16.26%)
Jim Simons 116,800 sh (-32.99%)
» More
Q2 2016

LGND Guru Trades in Q2 2016

Joel Greenblatt 71,870 sh (+229.35%)
Columbia Wanger 202,341 sh (+28.04%)
Paul Tudor Jones 4,400 sh (+12.82%)
Ken Fisher 72,390 sh (+2.56%)
Jim Simons 116,004 sh (-0.68%)
RS Investment Management 824,750 sh (-9.62%)
» More
» Details

Insider Trades

Latest Guru Trades with LGND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:NKTR, NAS:ARIA, OTCPK:ABCZY, NYSE:PBYI, OTCPK:LBTSF, NAS:BLUE, NAS:PRTA, NAS:KITE, NAS:OPHT, NAS:SRPT, NAS:AGIO, OTCPK:SOLTF, NAS:RARE, NAS:LXRX, NAS:ONCE, NAS:ITCI, NAS:DBVT, NAS:TBPH, NAS:ALDR, NAS:JUNO » details
Traded in other countries:LGDN.Germany,
Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Ligand Pharmaceuticals Inc was incorporated in Delaware in 1987. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. The Company has evaluated ASC 280 and has identified two reportable segments: the development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. and the biopharmaceutical company. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSKs Promacta (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza. The drug is also marketed in Spain under the brand name Conbriza through a co-promotion with Almirall, an international pharmaceutical company based in Spain. The Company currently has no manufacturing facilities. It currently outsource the production of Captisol to Hovione FarmaCiencia SA, or Hovione, a supplier of active pharmaceutical ingredients, or APIs and API intermediates located in Portugal. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.

Ratios

vs
industry
vs
history
P/E(ttm) 9.43
LGND's P/E(ttm) is ranked higher than
83% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. LGND: 9.43 )
Ranked among companies with meaningful P/E(ttm) only.
LGND' s P/E(ttm) Range Over the Past 10 Years
Min: 0.94  Med: 82.08 Max: 322.32
Current: 9.43
0.94
322.32
Forward P/E 20.83
LGND's Forward P/E is ranked lower than
86% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. LGND: 20.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 9.47
LGND's PE(NRI) is ranked higher than
85% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. LGND: 9.47 )
Ranked among companies with meaningful PE(NRI) only.
LGND' s PE(NRI) Range Over the Past 10 Years
Min: 7.19  Med: 100.74 Max: 99999999.99
Current: 9.47
7.19
99999999.99
Price/Owner Earnings (ttm) 1041.43
LGND's Price/Owner Earnings (ttm) is ranked lower than
99% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. LGND: 1041.43 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LGND' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 1.54  Med: 67.49 Max: 1376.33
Current: 1041.43
1.54
1376.33
P/B 5.43
LGND's P/B is ranked lower than
69% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. LGND: 5.43 )
Ranked among companies with meaningful P/B only.
LGND' s P/B Range Over the Past 10 Years
Min: 5.26  Med: 20.65 Max: 174.72
Current: 5.43
5.26
174.72
P/S 24.95
LGND's P/S is ranked lower than
69% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. LGND: 24.95 )
Ranked among companies with meaningful P/S only.
LGND' s P/S Range Over the Past 10 Years
Min: 4.63  Med: 18.89 Max: 714.32
Current: 24.95
4.63
714.32
PFCF 122.96
LGND's PFCF is ranked lower than
88% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. LGND: 122.96 )
Ranked among companies with meaningful PFCF only.
LGND' s PFCF Range Over the Past 10 Years
Min: 33.59  Med: 86.74 Max: 475.54
Current: 122.96
33.59
475.54
POCF 46.06
LGND's POCF is ranked lower than
75% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. LGND: 46.06 )
Ranked among companies with meaningful POCF only.
LGND' s POCF Range Over the Past 10 Years
Min: 41.89  Med: 63.7 Max: 3131.43
Current: 46.06
41.89
3131.43
EV-to-EBIT 57.02
LGND's EV-to-EBIT is ranked lower than
79% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. LGND: 57.02 )
Ranked among companies with meaningful EV-to-EBIT only.
LGND' s EV-to-EBIT Range Over the Past 10 Years
Min: -933.3  Med: -6.1 Max: 548.4
Current: 57.02
-933.3
548.4
EV-to-EBITDA 48.66
LGND's EV-to-EBITDA is ranked lower than
80% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. LGND: 48.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
LGND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -227.8  Med: -3.7 Max: 823.2
Current: 48.66
-227.8
823.2
Shiller P/E 27.20
LGND's Shiller P/E is ranked higher than
66% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. LGND: 27.20 )
Ranked among companies with meaningful Shiller P/E only.
LGND' s Shiller P/E Range Over the Past 10 Years
Min: 21.89  Med: 37.17 Max: 87.68
Current: 27.2
21.89
87.68
Current Ratio 0.57
LGND's Current Ratio is ranked lower than
93% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. LGND: 0.57 )
Ranked among companies with meaningful Current Ratio only.
LGND' s Current Ratio Range Over the Past 10 Years
Min: 0.28  Med: 1.68 Max: 12.94
Current: 0.57
0.28
12.94
Quick Ratio 0.56
LGND's Quick Ratio is ranked lower than
91% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. LGND: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
LGND' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 1.58 Max: 12.87
Current: 0.56
0.26
12.87
Days Inventory 177.11
LGND's Days Inventory is ranked lower than
65% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. LGND: 177.11 )
Ranked among companies with meaningful Days Inventory only.
LGND' s Days Inventory Range Over the Past 10 Years
Min: 33.18  Med: 79.07 Max: 151.94
Current: 177.11
33.18
151.94
Days Sales Outstanding 41.31
LGND's Days Sales Outstanding is ranked higher than
68% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. LGND: 41.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
LGND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.79  Med: 53.36 Max: 1057.37
Current: 41.31
5.79
1057.37
Days Payable 223.85
LGND's Days Payable is ranked higher than
85% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. LGND: 223.85 )
Ranked among companies with meaningful Days Payable only.
LGND' s Days Payable Range Over the Past 10 Years
Min: 197.62  Med: 282.1 Max: 822.72
Current: 223.85
197.62
822.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.30
LGND's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. LGND: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LGND' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.6  Med: -7.5 Max: 0.3
Current: 0.3
-18.6
0.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 25.55
LGND's Price/Tangible Book is ranked lower than
92% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. LGND: 25.55 )
Ranked among companies with meaningful Price/Tangible Book only.
LGND' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.02  Med: 20.27 Max: 206.67
Current: 25.55
6.02
206.67
Price/Projected FCF 4.89
LGND's Price/Projected FCF is ranked lower than
64% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. LGND: 4.89 )
Ranked among companies with meaningful Price/Projected FCF only.
LGND' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.35  Med: 7.36 Max: 98.86
Current: 4.89
5.35
98.86
Price/Median PS Value 1.37
LGND's Price/Median PS Value is ranked lower than
75% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. LGND: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
LGND' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 0.69 Max: 34.76
Current: 1.37
0.2
34.76
Price/Graham Number 3.28
LGND's Price/Graham Number is ranked lower than
60% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. LGND: 3.28 )
Ranked among companies with meaningful Price/Graham Number only.
LGND' s Price/Graham Number Range Over the Past 10 Years
Min: 1.56  Med: 2.46 Max: 3.83
Current: 3.28
1.56
3.83
Earnings Yield (Greenblatt) (%) 1.80
LGND's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. LGND: 1.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LGND' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 1.2 Max: 1.8
Current: 1.8
0.2
1.8

More Statistics

Revenue (TTM) (Mil) $88.06
EPS (TTM) $ 10.82
Beta0.91
Short Percentage of Float21.59%
52-Week Range $81.13 - 139.79
Shares Outstanding (Mil)20.85

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 118 158 210 260
EPS ($) 2.52 3.98 7.07 8.91
EPS w/o NRI ($) 2.52 3.98 7.07 8.91
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:LGND

Headlines

Articles On GuruFocus.com
Gurus Invest in Top Biotechnology Stocks Jun 20 2016 
RS Investment Increases Holdings in Ulta Salon, Noble Energy and Fortune Brands Dec 23 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Dan Loeb Sees Opportunity in Latest Activist Target Baxter International Aug 06 2015 
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 

More From Other Websites
Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III Sep 28 2016
Amgen's Multiple Myeloma Drug Bumbles Key Test Vs. Blockbuster Velcade Sep 27 2016
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : September 27, 2016 Sep 27 2016
Kite Pharma Reports Favorable Data from Lymphoma Study Sep 27 2016
Regeneron, Sanofi Skin Disease Drug Under Priority Review Sep 26 2016
Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps Sep 26 2016
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LGND-US :... Sep 26 2016
Ligand Inks CNS License Agreement with Seelos Therapeutics Sep 23 2016
Teva Reports Positive Phase III Tardive Dyskinesia Data Sep 23 2016
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 22 2016
Ligand Licenses Four Programs to Seelos Therapeutics Sep 22 2016
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology Sep 19 2016
ETF’s with exposure to Ligand Pharmaceuticals, Inc. : September 19, 2016 Sep 19 2016
Ligand Enters OmniAb® License Agreement with TeneoBio, Inc. Sep 16 2016
Ligand (LGND) Commences Phase II Type II Diabetes Study Sep 14 2016
5 Biotech Stocks That Are Broker Favorites Sep 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)